Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Pamlab, L.L.C. |
---|---|
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00321152 |
The purpose of the study is to test whether oral 6(S)-5-MTHF (Deplin®) is safe and effective in relieving depression when it is added to standard kinds of antidepressants called serotonin reuptake inhibitors (SSRIs).
Condition | Intervention | Phase |
---|---|---|
Major Depressive Disorder |
Drug: 6(S)-5-MTHF |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment |
Official Title: | A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF Among SSRI-Resistant Outpatients With Major Depressive Disorder (MDD) |
Estimated Enrollment: | 150 |
Study Start Date: | November 2006 |
Estimated Study Completion Date: | November 2008 |
Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
drug/drug = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
|
Drug: 6(S)-5-MTHF
The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (drug name: 6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
|
2: Experimental
placebo/drug = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
|
Drug: 6(S)-5-MTHF
The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (drug name: 6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
|
3: Placebo Comparator
placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
|
Drug: 6(S)-5-MTHF
The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (drug name: 6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
|
The study consists of two sequential phases, each lasting a total of four weeks (8 weeks total), with visits every 10 days. Once patients agree to participate in the study by signing the informed consent document, a full medical and psychiatric history will be taken and a physical examination and blood draw will be performed. Screen rating scales will be performed. Screened and eligible patients will be asked to return two weeks later for a baseline visit when they will be randomized to double-blind treatment with placebo or Deplin (drug name: 6(S)-5-MTHF). The double-blind treatment will last 60 days, during which patients will be seen every 10 days. Subjects will be randomized to one of three treatment groups: a)drug/drug, b) placebo/drug, c) placebo/placebo. Patients will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study
All patients will be asked to take two tablets of blinded study medication in the morning, in addition to their stable dose of ongoing SSRI treatment. Each study medication tablet will be either 7.5 mg of 6(S)-5-MTHF or matching placebo.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
University of California San Diego School of Medicine | |
San Diego, California, United States, 92161 | |
United States, Illinois | |
Rush University Medical Center, Psychiatric Medicine Associates, LLC | |
Chicago, Illinois, United States, 60612 | |
United States, Louisiana | |
Lousiana State University Health Sciences Center | |
New Orleans, Louisiana, United States, 70115 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
Burlington Medical Associates | |
Burlington, Massachusetts, United States, 01803 | |
Waltham Family Practice | |
Waltham, Massachusetts, United States, 02453 | |
Charles River Medical Associates | |
Westborough, Massachusetts, United States, 01581 | |
United States, Ohio | |
Univeristy of Cincinnati, College of Medicine | |
Cincinnati, Ohio, United States, 45267 | |
United States, Pennsylvania | |
University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, South Carolina | |
Southeast Health Consultants, LLC | |
Charleston, South Carolina, United States, 29407 | |
United States, Tennessee | |
Vanderbilt University Medical Center | |
Nashville, Tennessee, United States, 37212 |
Principal Investigator: | George I Papakostas, M.D | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital ( George Papakostas ) |
Study ID Numbers: | 2006P000604 |
Study First Received: | May 1, 2006 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00321152 |
Health Authority: | United States: Institutional Review Board |
Depression Mental Disorders Mood Disorders Depressive Disorder, Major |
Depressive Disorder Serotonin Behavioral Symptoms |
Pathologic Processes Disease |